KR101590236B1 - 카세인 키나제 억제제로서의 신규한 융합된 피리딘 화합물 - Google Patents
카세인 키나제 억제제로서의 신규한 융합된 피리딘 화합물 Download PDFInfo
- Publication number
- KR101590236B1 KR101590236B1 KR1020137015822A KR20137015822A KR101590236B1 KR 101590236 B1 KR101590236 B1 KR 101590236B1 KR 1020137015822 A KR1020137015822 A KR 1020137015822A KR 20137015822 A KR20137015822 A KR 20137015822A KR 101590236 B1 KR101590236 B1 KR 101590236B1
- Authority
- KR
- South Korea
- Prior art keywords
- pyrrolo
- dihydro
- pyridin
- pyrazol
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C*(C)(C)Cc1cccc(C(C(*)c2c(CN(*)C3=O)c3ncc2)N*)c1 Chemical compound C*(C)(C)Cc1cccc(C(C(*)c2c(CN(*)C3=O)c3ncc2)N*)c1 0.000 description 5
- CHSFPCMJLAXYGH-UHFFFAOYSA-N C[n](cc1-c2ccnc(C(O3)=O)c2C3=O)nc1-c(cc1)ccc1F Chemical compound C[n](cc1-c2ccnc(C(O3)=O)c2C3=O)nc1-c(cc1)ccc1F CHSFPCMJLAXYGH-UHFFFAOYSA-N 0.000 description 2
- YDKJAGABVYOSFF-UHFFFAOYSA-N C[n](cc1-c(ccnc2C#N)c2C#N)nc1-c(cc1)ccc1F Chemical compound C[n](cc1-c(ccnc2C#N)c2C#N)nc1-c(cc1)ccc1F YDKJAGABVYOSFF-UHFFFAOYSA-N 0.000 description 1
- CDCJBGKVPSRLNL-UHFFFAOYSA-N C[n](cc1-c2c(C(O)=O)c(C(O)=O)ncc2)nc1-c(cc1)ccc1F Chemical compound C[n](cc1-c2c(C(O)=O)c(C(O)=O)ncc2)nc1-c(cc1)ccc1F CDCJBGKVPSRLNL-UHFFFAOYSA-N 0.000 description 1
- XISSYJGQGSMWHO-UHFFFAOYSA-N C[n](cc1-c2ccnc(CO3)c2C3=O)nc1-c(cc1)ccc1F Chemical compound C[n](cc1-c2ccnc(CO3)c2C3=O)nc1-c(cc1)ccc1F XISSYJGQGSMWHO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061425213P | 2010-12-20 | 2010-12-20 | |
| US61/425,213 | 2010-12-20 | ||
| PCT/IB2011/055489 WO2012085721A1 (en) | 2010-12-20 | 2011-12-06 | Novel fused pyridine compounds as casein kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20130121126A KR20130121126A (ko) | 2013-11-05 |
| KR101590236B1 true KR101590236B1 (ko) | 2016-01-29 |
Family
ID=45446116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137015822A Expired - Fee Related KR101590236B1 (ko) | 2010-12-20 | 2011-12-06 | 카세인 키나제 억제제로서의 신규한 융합된 피리딘 화합물 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8536164B2 (enExample) |
| EP (2) | EP3181133B1 (enExample) |
| JP (2) | JP5684923B2 (enExample) |
| KR (1) | KR101590236B1 (enExample) |
| CN (1) | CN103260622B (enExample) |
| AR (1) | AR084412A1 (enExample) |
| AU (1) | AU2011346733C1 (enExample) |
| CA (1) | CA2819961C (enExample) |
| CY (2) | CY1118772T1 (enExample) |
| DK (2) | DK2654750T3 (enExample) |
| ES (2) | ES2623387T3 (enExample) |
| HR (2) | HRP20170484T1 (enExample) |
| HU (2) | HUE047089T2 (enExample) |
| IL (1) | IL226948A (enExample) |
| LT (2) | LT2654750T (enExample) |
| MX (1) | MX338551B (enExample) |
| PL (2) | PL2654750T3 (enExample) |
| PT (2) | PT2654750T (enExample) |
| RS (2) | RS59098B1 (enExample) |
| SG (1) | SG190802A1 (enExample) |
| SI (2) | SI3181133T1 (enExample) |
| WO (1) | WO2012085721A1 (enExample) |
| ZA (1) | ZA201303453B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20140252T1 (hr) * | 2009-10-28 | 2014-04-25 | Pfizer Inc. | Derivati imidazola kao inhibitori kazeinske kinaze |
| US9938269B2 (en) * | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| EP2935272B1 (en) * | 2012-12-21 | 2017-02-22 | Bristol-Myers Squibb Company | Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors |
| WO2015163446A1 (ja) * | 2014-04-25 | 2015-10-29 | 協和発酵キリン株式会社 | イミダゾール化合物の製造方法 |
| JP2017222576A (ja) * | 2014-10-31 | 2017-12-21 | 石原産業株式会社 | 有害生物防除剤 |
| CN107365315B (zh) * | 2016-05-11 | 2024-08-09 | 国药集团国瑞药业有限公司 | 一种吡唑类化合物、其晶型及其制备方法 |
| US10973820B2 (en) | 2017-12-13 | 2021-04-13 | Facio Intellectual Property B.V. | Compounds for treatment of diseases related to DUX4 expression |
| TW202112368A (zh) * | 2019-06-13 | 2021-04-01 | 荷蘭商法西歐知識產權股份有限公司 | 用於治療有關dux4表現之疾病的抑制劑組合 |
| CN115298183A (zh) * | 2020-03-27 | 2022-11-04 | 北京原基华毅生物科技有限公司 | 作为酪蛋白激酶抑制剂的化合物 |
| WO2021190616A1 (en) * | 2020-03-27 | 2021-09-30 | Gritscience Biopharmaceuticals Co., Ltd. | Methods for inhibiting casein kinases |
| AR122711A1 (es) | 2020-06-25 | 2022-09-28 | Alchemedicine Inc | COMPUESTO HETEROCÍCLICO COMO INHIBIDOR DE CASEÍNA QUINASA 1d Y/O QUINASA 5 TIPO RECEPTOR DE ACTIVINA |
| CN111808102B (zh) * | 2020-08-03 | 2021-12-31 | 南通大学 | 一种3-甲氧基-6,7-二氢-5H-吡咯并[3,4-b]吡啶盐酸盐及其合成方法 |
| KR20230069169A (ko) * | 2020-09-17 | 2023-05-18 | 얀센 파마슈티카 엔.브이. | 카제인 키나제 1 델타 조절제 |
| JP2023541465A (ja) * | 2020-09-17 | 2023-10-02 | ヤンセン ファーマシューティカ エヌ．ベー． | カゼインキナーゼ１デルタモジュレーター |
| WO2022115301A1 (en) * | 2020-11-24 | 2022-06-02 | Merck Sharp & Dohme Corp. | Modified isoindolinones as glucosylceramide synthase inhibitors |
| CN116888126A (zh) * | 2020-12-15 | 2023-10-13 | 北京原基华毅生物科技有限公司 | 一种酪蛋白激酶抑制剂的化合物 |
| US20230053307A1 (en) * | 2021-07-19 | 2023-02-16 | Buddhist Tzu Chi Medical Foundation | Method for preventing or treating skin disorders and conditions |
| CN119487030A (zh) * | 2022-06-14 | 2025-02-18 | 北京原基华毅生物科技有限公司 | 作为酪蛋白激酶抑制剂的化合物的盐和/或晶形 |
| CN117362303A (zh) * | 2022-07-02 | 2024-01-09 | 黑龙江联顺生物科技有限公司 | 一种生物素中间体环酐的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0151962A3 (en) | 1984-01-25 | 1985-10-02 | Beecham Group Plc | Pyrazolopyridine derivatives |
| IL132991A (en) * | 1997-05-22 | 2005-11-20 | Searle & Co | Substituted pyrazoles, pharmaceutical compositionscomprising them and their use as p38 inase inhibi tors |
| ATE299881T1 (de) * | 1999-12-21 | 2005-08-15 | Sugen Inc | 4-substituierte 7-aza-indolin-2-one und ihre anwendung als protein kinase inhibitoren |
| DK1906965T3 (en) | 2005-06-22 | 2015-08-03 | Chemocentryx Inc | Azaindazol compounds and methods of use thereof |
| WO2007140213A1 (en) | 2006-05-26 | 2007-12-06 | Forest Laboratories Holdings Limited | Pyridoazepine derivatives |
| EP2308866A1 (de) * | 2009-10-09 | 2011-04-13 | Bayer CropScience AG | Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide |
| HRP20140252T1 (hr) * | 2009-10-28 | 2014-04-25 | Pfizer Inc. | Derivati imidazola kao inhibitori kazeinske kinaze |
-
2011
- 2011-12-06 EP EP17151228.8A patent/EP3181133B1/en active Active
- 2011-12-06 KR KR1020137015822A patent/KR101590236B1/ko not_active Expired - Fee Related
- 2011-12-06 RS RS20191036A patent/RS59098B1/sr unknown
- 2011-12-06 JP JP2013545540A patent/JP5684923B2/ja active Active
- 2011-12-06 AU AU2011346733A patent/AU2011346733C1/en not_active Ceased
- 2011-12-06 RS RS20170387A patent/RS55897B1/sr unknown
- 2011-12-06 EP EP11805210.9A patent/EP2654750B1/en active Active
- 2011-12-06 PL PL11805210T patent/PL2654750T3/pl unknown
- 2011-12-06 ES ES11805210.9T patent/ES2623387T3/es active Active
- 2011-12-06 SI SI201131784T patent/SI3181133T1/sl unknown
- 2011-12-06 LT LTEP11805210.9T patent/LT2654750T/lt unknown
- 2011-12-06 LT LTEP17151228.8T patent/LT3181133T/lt unknown
- 2011-12-06 HR HRP20170484TT patent/HRP20170484T1/hr unknown
- 2011-12-06 DK DK11805210.9T patent/DK2654750T3/en active
- 2011-12-06 HU HUE17151228A patent/HUE047089T2/hu unknown
- 2011-12-06 ES ES17151228T patent/ES2744099T3/es active Active
- 2011-12-06 MX MX2013005833A patent/MX338551B/es active IP Right Grant
- 2011-12-06 HU HUE11805210A patent/HUE032405T2/en unknown
- 2011-12-06 CA CA2819961A patent/CA2819961C/en active Active
- 2011-12-06 SG SG2013036934A patent/SG190802A1/en unknown
- 2011-12-06 PT PT118052109T patent/PT2654750T/pt unknown
- 2011-12-06 CN CN201180061257.2A patent/CN103260622B/zh active Active
- 2011-12-06 PL PL17151228T patent/PL3181133T3/pl unknown
- 2011-12-06 PT PT17151228T patent/PT3181133T/pt unknown
- 2011-12-06 DK DK17151228.8T patent/DK3181133T3/da active
- 2011-12-06 WO PCT/IB2011/055489 patent/WO2012085721A1/en not_active Ceased
- 2011-12-06 SI SI201131141A patent/SI2654750T1/sl unknown
- 2011-12-13 US US13/323,883 patent/US8536164B2/en active Active
- 2011-12-19 AR ARP110104787A patent/AR084412A1/es not_active Application Discontinuation
-
2013
- 2013-05-13 ZA ZA2013/03453A patent/ZA201303453B/en unknown
- 2013-06-13 IL IL226948A patent/IL226948A/en active IP Right Grant
-
2015
- 2015-01-14 JP JP2015005142A patent/JP5876596B2/ja active Active
-
2017
- 2017-03-27 CY CY20171100378T patent/CY1118772T1/el unknown
-
2019
- 2019-08-14 HR HRP20191469 patent/HRP20191469T1/hr unknown
- 2019-08-21 CY CY20191100892T patent/CY1122062T1/el unknown
Non-Patent Citations (1)
| Title |
|---|
| J. Med. Chem., 2009, 52, 7618-7630 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101590236B1 (ko) | 카세인 키나제 억제제로서의 신규한 융합된 피리딘 화합물 | |
| AU2018388406B2 (en) | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors | |
| CA2897333C (en) | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors | |
| JP6860507B2 (ja) | Ｔｎｆ活性のモジュレーターとしてのベンゾオキサジノン誘導体およびその類似体 | |
| CA2821712C (en) | Substituted n-(1h-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type iii receptor tyrosine kinase inhibitors | |
| AU2017288755B2 (en) | Novel compound or pharmaceutically acceptable salt thereof | |
| KR101421852B1 (ko) | 카세인 키나제 억제제로서의 이미다졸 유도체 | |
| KR20220061958A (ko) | Cd38의 억제제로서의 헤테로바이사이클릭 아미드 | |
| CA2921880A1 (en) | Alkynyl alcohols and methods of use | |
| AU2021232727A1 (en) | Nuclear receptor modulators | |
| CA2705405A1 (en) | New compounds | |
| CA3092770A1 (en) | Substituted imidazolidin-2-one derivatives as prmt5 inhibitors | |
| KR20210108433A (ko) | 티에노피리디논 화합물 | |
| HK1188145B (en) | Novel fused pyridine compounds as casein kinase inhibitors | |
| TW202540097A (zh) | ２，３—二氫吡咯并吡啶甲醯胺化合物及其使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E90F | Notification of reason for final refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| FPAY | Annual fee payment |
Payment date: 20181227 Year of fee payment: 4 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-5-5-R10-R11-asn-PN2301 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-5-5-R10-R14-asn-PN2301 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 6 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 7 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 8 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20240126 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20240126 |